Humira licensed for psoriasis

Humira (adalimumab) is now licensed for moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant of other systemic therapy, including ciclosporin, methotrexate or PUVA.

View Humira drug record

Further information: Abbott

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more